OBJECTIVE: Lipopolysaccharide-binding protein (LBP) is a 65-kDa acute-phase protein present in blood at high concentrations, known to be derived from the liver. We aimed to gain insights into the association of circulating LBP with insulin resistance in humans and mice. METHODS, DESIGN AND MEASUREMENTS: We studied the cross-sectional (n ¼ 222) and weight loss-induced (n ¼ 34) associations of LBP (enzyme-linked immunosorbent assay) with inflammatory and metabolic parameters (including minimal model-measured insulin sensitivity), and the effects of high-fat diet (HFD), metformin and genetic insulin sensitization (glucagon-like peptide 1 receptor knockout model) in mice. RESULTS: Circulating LBP concentration was significantly increased in subjects with type 2 diabetes and dramatically increased in subjects with morbid obesity. LBP was significantly associated with insulin sensitivity and different inflammatory markers and decreased after weight loss (22.2 ± 5.8 vs 16.2 ± 9.3 mg ml
INTRODUCTION
In recent years, it has become evident that alterations in the function of the innate immune system are intrinsically linked to metabolic pathways. 1 -5 Immune system homeostasis is challenged by continuous external insults, like saturated fatty acid-rich diets, 6 pathogen-associated molecular patterns like lipopolysaccharide (LPS), 7 burden of infection 8 and oxidative stress. 9 These continuous insults could result in a chronic low-level inflammation associated with insulin resistance. Lipopolysaccharide-binding protein (LBP) is a 65-kDa protein, an acute-phase reactant predominantly derived from the liver, present in blood at high concentrations (approximately 2-20 mg ml
À1
). 10 LBP plasma levels increase dramatically after inflammatory challenges, including bacterial sepsis. 10 Although the molecular structure of LBP is not entirely known, LBP clearly binds LPS (and LPS substructures, such as lipid IVa) through recognition of lipid A. 11 The plasma protein LBP dramatically accelerates binding of LPS monomers from aggregates to CD14, 12 thereby enhancing the sensitivity of cells to LPS. Furthermore, LBP acts as a lipid transfer protein, a function in keeping with its sequence homology to lipid transferases (phospholipid transfer protein and cholesterol ester transfer protein). LBP co-purifies with high-density lipoprotein (HDL) particles and additional studies have shown that LBP can transfer LPS to lipoproteins, neutralizing LPS effects. 13 Serum LBP concentration was described as a marker of coronary artery disease 14, 15 and has been recently found to be associated with obesity and related disorders in apparently healthy Chinese subjects. 16 We here confirm the previously reported association of circulating LBP with insulin resistance and obesity in a Caucasian population. 14 To gain insights into these associations, we investigated the effects of diet weight loss in humans and the effects of high-fat diet (HFD), metformin and genetic insulin sensitization (glucagon-like peptide 1 receptor knockout (GLPIR KO) model) in mice.
MATERIALS AND METHODS
Cross-sectional study Participants' recruitment. A total of 222 Caucasian men were recruited and studied. In all, 142 of them were recruited in an ongoing study dealing with non-classical cardiovascular risk factors in Northern Spain. Subjects were randomly localized from a census and they were invited to participate. The participation rate was 71%. A 75-g oral glucose tolerance test according to the American Diabetes Association criteria was performed in all subjects. All subjects with normal glucose tolerance (NGT) (n ¼ 87) had fasting plasma glucose o7.0 mM and 2-h post-load plasma glucose o7.8 mM after a 75-g oral glucose tolerance test. Glucose intolerance (GIT) was diagnosed in 40 subjects according to the American Diabetes Association criteria (post-load glucose between 7.8 and
mmol l À1
). Previously unknown type 2 diabetes (T2DM) was diagnosed in 15 of these 142 subjects (post-load glucose higher than 11.1 mmol l À1 ). Inclusion criteria were as follows: (1) body mass index (BMI) o40 kg m À2 , (2) absence of systemic disease and (3) absence of infection within the previous month, which was determined by history and verified by analysis of white blood cells count. None of the control subjects were under medication or had evidence of metabolic disease other than obesity. Alcohol and caffeine were withheld within 12 h of performing the insulin sensitivity test. Liver disease and thyroid dysfunction were specifically excluded by biochemical work-up.
To increase the statistical power of the group of patients with T2DM, 80 patients were prospectively recruited from diabetes outpatient clinics. Data from these patients were merged with those from the recently diagnosed type 2 diabetic patients. Exclusion criteria for patients with T2DM included the following: (1) clinically significant hepatic, neurological, endocrinological or other major systemic disease, including malignancy; (2) history or current clinical evidence of hemochromatosis; (3) history of drug or alcohol abuse, defined as 480 g per day in men and 440 g per day in women, or serum transaminase activity more than twice the upper limit of normality; (4) an elevated serum creatinine concentration; (5) acute major cardiovascular event in the previous 6 months; (6) acute illnesses and current evidence of acute or chronic inflammatory or infective diseases and (7) mental illness rendering subjects unable to understand the nature, scope and possible consequences of the study. Pharmacological treatment for these patients was: insulin: 29 patients; metformin: 35 patients; sulfonylureas, 43 patients; statins: 28 patients; fibrates: 9 patients; blood pressure-lowering agents: 32 patients; aspirin: 16 patients and allopurinol: 3 patients. All subjects gave written informed consent after the purpose of the study was explained to them. The Institutional Review Board of the institution approved the protocol.
Measurements
Subjects were studied in the post-absorptive state. BMI was calculated as weight (in kilograms) divided by height (in meters) squared. Subjects' waists were measured using a soft tape midway between the lowest rib and the iliac crest; hip circumference was measured at the widest part of the gluteal region; and waist-to-hip ratio was accordingly calculated. Fat mass, percentage fat mass and fat-free mass were calculated using bioelectric impedance (Holtain BC Analyzer, Holtain, Cambridge, UK).
Study of insulin sensitivity
Insulin sensitivity was measured using the frequently sampled intravenous glucose tolerance test (FSIVGTT) on a different day in those subjects who agreed (n ¼ 142). In brief, basal blood samples were drawn at À15 and À5 min, after which glucose (300 mg kg À1 body weight) was injected over 1 min starting at time 0. At 20 min, regular insulin (Actrapid, Novo, Denmark; 0.03 U kg À1 ) was injected as a bolus. Additional samples were obtained from a contralateral antecubital vein at times 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 20, 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90 , 100, 120, 140, 160 and 180 min. Samples were rapidly collected through a three-way stopcock connected to the butterfly needle. Data from the FSIVGTT were submitted to computer programs that calculate the characteristic metabolic parameters by fitting glucose and insulin to the minimal model that describes the time course of glucose and insulin concentrations. The glucose disappearance model, by accounting for the effect of insulin and glucose on glucose disappearance, provides the parameters S I (10 -4) per minute per microunit per milliliter) or the insulin sensitivity index, a measure of the effect of insulin concentrations above the basal level to enhance glucose disappearance. Estimation of model parameters was performed according to the MINMOD computer program. 17 
Analytical methods
Serum glucose concentrations were measured in duplicate by the glucose oxidase method using a Beckman glucose analyzer II (Beckman Instruments, Brea, CA, USA). Glycosylated hemoglobin (HbA1c) was measured by the high-performance liquid chromatography method (Bio-Rad, Muenchen, Germany, and autoanalyser Jokoh HS-10, respectively). Intra-and inter-assay coefficients of variation were o4% for all these tests.
Serum insulin was measured in duplicate by a monoclonal immunoradiometric assay (Medgenix Diagnostics, Fleunes, Belgium). The intra-assay coefficient of variation was 5.2% at a concentration of 10 mU l À1 and 3.4%
at 130 mU l À1 . The inter-assay coefficients of variation were 6.9 and 4.5% at 14 and 89 mU l
À1
, respectively. Total serum cholesterol was measured through the reaction of cholesterol esterase/cholesterol oxidase/peroxidase, using Hitachi 747 (Hitachi, Bohemia, NY, USA). HDL cholesterol was quantified after precipitation with polyethylene glycol at room temperature. Low-density lipoprotein cholesterol was calculated using the Friedewald formula. Total serum triglycerides were measured through the reaction of glycerol/ phosphate/oxidase and peroxidase.
Serum LBP levels were measured by human and mouse LBP enzymelinked immunosorbent assay (ELISA) kit (HyCult biotechnology b.v.). Serum soluble tumor necrosis factor receptors 1 and 2 (sTNFR2 and sTNFR1) concentration was measured by sTNF-RII EASIATM ELISA kit and sTNF-RI EASIATM ELISA kit, respectively (Biosource Europe S.A., Nivelles, Belgium). Serum samples were diluted and assayed according to the manufacturer's instructions. Intra-and inter-assay coefficients of variation for all these determinations were between 5 and 10%.
Serum C-reactive protein (ultrasensitive assay; Beckman, Fullerton, CA, USA) was determined by routine laboratory test, with intra-and inter-assay coefficients of variation o4%. The lower limit of detection was 0.02 mg l À1 . Plasma bactericidal/permeability-increasing protein levels were measured by human bactericidal/permeability-increasing ELISA kit (HyCult Biotechnology b.v.). Plasma and serum samples were diluted and assayed according to the manufacturer's instructions. Intra-and inter-assay coefficients of variation for all these determinations were between 5 and 10%. To prevent activation of neutrophils, blood was drawn into tubes containing EDTA as anticoagulant and kept at 4 1C. Whole blood was centrifuged within 3 h at 3000 Â g for 10 min at 4 1C, and finally the plasma supernatant was removed and stored at À80 1C. Serum leptin concentrations were measured by human Leptin ELISA kit (Biovendor GmbH, Heidelberg, Germany). Intra-and inter-assay coefficients of variation were between 3 and 9%. Complement factor B ELISA was performed as reported previously. 18 Endotoxin (LPS) was measured by a limulus amebocyte lysate test (QCL-1000; Lonza Iberica S.A. Barcelona, Spain), as recommended by the manufacturer, in a subgroup of 30 participants (19 with NGT and 11 with altered glucose tolerance). Serum was collected in nonpyrogenic tubes and frozen at À20 1C until assay. All procedures were performed under non-pyrogenic conditions. Serum was heat inactivated at 75 1C for 10 min. Inactivated serum was diluted 1:5, mixed with limulus amebocyte lysate and incubated at 37 1C for 10 min. A substrate solution was then mixed with the limulus amebocyte lysate sample and incubated at 37 1C for an additional 6 min. The reaction was stopped with a stop reagent. If endotoxin was present in the serum, a yellow color would have developed. The reaction was read at 405 nm. Recovery of spiked LPS was between 50 and 200%. Sensitivity of the assay was 0.005 Ehrlich units ml À1 (0.5 pg ml
). Intra-and inter-assay coefficients of variation for LPS determinations were between 5 and 10%.
Weight loss study
In all, 34 Caucasian obese volunteers (17 women and 17 men) attending the Endocrinology Department at the University Clinic of Navarra were recruited. Patients underwent a clinical assessment including medical history, physical examination, body composition analysis, comorbidity evaluation and nutritional interviews performed by a multidisciplinary consultation team. All subjects were non-smokers. Patients with signs of infection were excluded. Obese patients were not receiving statins or antidiabetic medication.
Weight loss was achieved by prescription of a diet during 4 months providing a daily energy deficit of 500 -1000 kcal per day as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA, USA) and multiplication by 1.4 as indicated for sedentary individual's to obtain the patient's total energy expenditure. This hypocaloric regime allows a safe and steady weight loss of 0.5 -1.0 kg per week when followed and supplied 30, 54 and 16% of energy requirements in the form of fat, carbohydrates and protein, respectively.
In this study, body fat was estimated by air-displacement-plethysmography (Bod-Pod, Life Measurements, Concord, CA, USA).
The Institutional Review Board of the institution approved the protocol; hence, we certify that all applicable institutional regulations regarding the ethical use of information and samples from human volunteers were followed during this research.
In the weight loss study, plasma glucose was analyzed using an automated analyzer (Roche/Hitachi Modular P800; Roche, Basel, Switzerland) as described previously. 19 Insulin was measured using an enzyme-amplified chemiluminescence assay (Immulite, Diagnostic Products Corp., Los Angeles, CA, USA). To estimate insulin resistance, the homeostasis model assessment (HOMA) index was calculated as fasting insulin concentration (mU ml Animal models GLP-1R KO experiment. Eleven-week-old C57Bl/6J wild-type mice (Charles River Laboratory, l'Arbresle, France) and GLP-1 receptor knockout mice (GLP-1Rr À1 / À1 ), on a C57BL/6J background, from our animal facility) were conventionally housed in Rangueil Hospital (Toulouse, France) animal facility with a constant temperature (20 -22 1C) , humidity (50 -60%), an inverted light cycle (light off at 1000 hours) and free access to food and water. Mice were fed a high-fat, carbohydrate-free diet for 4 weeks. The diet contained B72% fat (corn oil and lard), 28% protein and o1% carbohydrate, as energy content. This diet has been shown to induce diabetes before an increase in body weight. 20 Animals were handled in accordance with the principles and guidelines established by the National Institute of Medical Research.
Metformin treatment. At the beginning of the HFD or normal chow, C57Bl/6J wild-type mice were orally treated with metformin (Sigma, Saint-Quentin Fallavier, France) at the dose of 300 mg kg À1 per day per mouse or water (vehicle), all along the diet treatment, that is, for 1 month.
Six mice were used for each treatment in all experiments. Blood was collected from the retro-orbital cavity of 6-h-fasted mice by heparinized glass tubes and then centrifuged at 4 1C for 5 min at 8000 r.p.m.
Plasma was then separated from the cellular portion and snap frozen in liquid nitrogen. For fed insulin values, blood was collected from the tail vein.
Glucose tolerance test. Six-hour-fasted mice were injected intraperitoneally with glucose (1 g kg
À1
). Blood was collected from the tail vein at À30, 0, 30, 60 and 90, and glycemia measured using a glucometer (Accucheck Actine, Roche).
Statistical methods
Statistical analyses were performed using SPSS 12.0 software (SPSS, Chicago, IL, USA). Unless otherwise stated, descriptive results of continuous variables are expressed as mean and s.d. for Gaussian variables or median and interquartile range. Parameters that did not fulfill normal distribution were mathematically transformed to improve symmetry for subsequent analyses. The relationship between variables was analyzed by simple correlation (Pearson's test and Spearman's test) and multiple regression analyses. One-factor analysis of variance with post hoc Bonferroni's test was used to compare clinical variables and circulating LBP according to glucose tolerance and obesity status. Paired t-tests were used to compare baseline and post-weight loss subjects. Levels of statistical significance were set at Po0.05. For a given value of P ¼ 0.05, the study had a 98% power to detect significant correlations between circulating LBP and metabolic parameters (Pearson's coefficient of at least 0.30) in bilateral tests in all subjects studied, and a 91% power in altered glucose tolerance subjects.
RESULTS

Cross-sectional study
As recently confirmed by other authors, 16 circulating LBP concentration were significantly increased in subjects with T2DM compared with subjects with GIT and with NGT (Po0.001) ( Table 1 and Figure 1a ). The increase in circulating LBP concentration was especially remarkable in subjects with morbid obesity (Figures 1a  and b) .
In all subjects, circulating LBP was significantly and positively associated with BMI (r ¼ 0.3, Po0.0001), waist-to-hip ratio (r ¼ 0. negatively with HDL-cholesterol (r ¼ À0.28, Po0.0001) and insulin sensitivity (r ¼ À0.19, P ¼ 0.02).
In GIT and T2DM subjects, circulating LBP concentration was robustly associated with obesity measures (BMI or waist-to-hip ratio), metabolic (HbA1c) and inflammatory markers (sTNFR2 and sTNFR1), and inversely with insulin sensitivity (Figure 2b ) and HDL cholesterol (Table 2a ). In subjects with NGT, no significant associations between circulating LBP and these variables were found (Table 2a) .
Obesity and inflammatory markers were the main factors associated with circulating LBP in subjects with GIT, because BMI (P ¼ 0.02) and sTNFR2 (P ¼ 0.045) contributed independently to circulating LBP variance, after controlling for the effects of age, HbA1c and HDL-cholesterol in a multiple linear regression analysis (Table 2b) . In T2DM subjects, BMI (Po0.001) and HbA1c (P ¼ 0.02) also contributed independently to circulating LBP variance, after controlling for effects of age, sTNFR2 and HDL-cholesterol (Table 2b) .
In all subjects, circulating LBP was also associated with other possible candidate markers of obesity-related insulin resistance, such as circulating C-reactive protein (r ¼ 0.18, P ¼ 0.02), bactericidal/permeability-increasing (r ¼ À0.3, Po0.001) and complement factor B (r ¼ 0.5, Po0.0001) concentrations.
To corroborate the interaction between LBP and endotoxin (LPS), we measured circulating LPS in 30 participants (19 with NGT and 11 with altered glucose tolerance). Circulating LBP was significantly associated with LPS levels in both groups (r ¼ 0.60, P ¼ 0.006 in NGT and r ¼ 0.77, P ¼ 0.008 in altered glucose tolerance participants).
Diet-weight loss study These observations led us to explore an independent cohort in which we also evaluated the effects of weight loss.
Anthropometrical and clinical variables of these subjects are shown in Table 3a . In this cohort of subjects, baseline LBP concentration significantly correlated with BMI (r ¼ 0.45, P ¼ 0.007), fat mass (r ¼ 0.44, P ¼ 0.01), circulating leptin (r ¼ 0.39, P ¼ 0.02) and complement factor B (r ¼ 0.54, P ¼ 0.001) concentration. Circulating LBP concentration was significantly decreased after weight loss (from 22.2±5.8 to 16.2±9.3 mg ml À1 , Po0.0001) (Table 3a and Figure 2c ). The change in LBP concentration after weight loss was significantly associated with the change in BMI (r ¼ 0.39, P ¼ 0.02), fat mass (r ¼ 0.35, P ¼ 0.04), fasting insulin (r ¼ 0.56, P ¼ 0.01) and HOMA index (r ¼ 0.54, P ¼ 0.01) (Table 3b ). In a multiple linear regression analysis, the change in BMI (P ¼ 0.005) contributed independently to the change in circulating LBP variance, after controlling for change in the HOMA index after weight loss. Furthermore, the decrease in LBP concentration after weight loss was significantly associated with the decrease in complement factor B (r ¼ 0.67, Po0.0001) and leptin (r ¼ 0.43, P ¼ 0.01) concentration (Table 3b ). Circulating LPS also significantly decreased after weight loss (from 0.163 (0-0.379) to 0.03 (0-0.227) EU ml
À1
, P ¼ 0.02) (Figure 2c ). The change in LPS concentration after weight loss was significantly associated with the change in fat mass (r ¼ 0.42, P ¼ 0.01). In a multiple linear regression analysis, BMI (P ¼ 0.02) contributed independently to circulating LBP variance, after controlling for the change of LPS after weight loss.
Findings in mice models. Consistent with the previous findings, circulating LBP concentration were significantly decreased in a mouse model of insulin sensitization, glucagon-like peptide 1 receptor knockout mice (P ¼ 0.009) 21 ( Figures 3a and b ) and after metformin administration in mice fed a normal chow diet (Figure 4a) , and increased in mice fed a HFD (Figure 4a ). When metformin was administered in mice fed a HFD, the decrease in LBP concentration was not significant (Figure 4a ). The effects of metformin and HFD on glucose tolerance were monitored 
DISCUSSION
Lipopolysaccharide is a strong stimulatory inductor of the release of several cytokines that are key inducers of insulin resistance and is a putative factor for the triggering of metabolic disturbances. A recent article has demonstrated that metabolic concentrations of plasma LPS are a sufficient molecular mechanism for triggering insulin resistance, obesity and T2DM. 20 This process was named Abbreviations: BMI, body mass index; BPI, bactericidal/permeability-increasing protein; CFB, complement factor B; CRP, C-reactive protein; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LBP, lipopolysaccharide-binding protein; LDL, low-density lipoprotein; SBP, systolic blood pressure; sTNFR, soluble tumor necrosis factor receptor; WHR, waist-to-hip ratio. metabolic endotoxemia, in which day-to-day circulating endotoxin (LPS) affects inflammation-induced and HFD (with 72% fat (corn oil and lard) and 28% protein)-induced metabolic diseases, but metabolic LPS concentration was not enough to produce acute endotoxemia. Cani et al. showed that high-fat feeding strongly increased intestinal permeability and reduced the expression of genes coding for proteins of the tight junctions. This process could be a possible mechanism that could increase intestinal permeability allowing LPS access in the bloodstream. 22 The physiological LBP role in the innate immune system is to help in the macrophage response to LPS, enhancing the complex CD14 -LPS interaction and increasing LPS sensibility in the host. LBP could carry the potential of a diagnostic marker in sepsis and invasive infections. 23, 24 Thus, the high circulating LBP concentration associated with insulin resistance and obesity could reflect the physiological response to LPS-associated metabolic disturbances. However, the decrease in circulating LBP concentration was associated with the decrease in fat mass after weight loss and not with the decrease in LPS. Otherwise, we cannot exclude that the lack of association between the decrease in LBP concentration and the decrease of LPS levels could be caused by the technical limitation for direct LPS measurement in serum samples. In fact, the limulus amebocyte lysate test used in this current study is sensitive to several nonspecific activators and inhibitors in serum; it is difficult to accurately quantify low levels of LPS in serum.
The main findings of this manuscript are:
(1) The strong relationship between circulating LBP and obesity, previously reported, 14, 16 mainly in subjects with GIT and T2DM. In a previous cross-sectional study, we have reported that plasma LBP was positively associated with several components of the metabolic syndrome and negatively associated with insulin sensitivity 14 in non-diabetic subjects. In this cross-sectional study, we report associations in subjects with GIT and in subjects with T2DM. In addition, an independent contribution of BMI to LBP concentration variance was found in subjects with GIT and T2DM.
(2) The decrease in circulating LBP and LPS in parallel with weight loss-induced changes in fat mass and insulin resistance. The effects of high-fat diet (HFD) and metformin on the area under the 2-h blood glucose response curve (AUC, mmol Á min) and on body weight gain. (c) Circulating LPS levels in serum from mice fed a high-fat diet vs normal chow and in serum from mice after metformin administration.
(3) The decreased levels of circulating LBP concentration in glucagon-like peptide 1 receptor knockout mice (more insulin sensitive than wild type) 21 and in response to metformin. (4) The increased LBP levels after HFD in comparison with normal chow diet in mice, thus confirming the recent findings from Naito et al. 25 in four different murine models with obesity and/or diabetes in comparison with lean C57BL/6J mice fed a normal diet. In a former study, the authors demonstrated that oral administration of Lactobacillus casei Shirota accelerated the decrease in plasma glucose levels during insulin tolerance test in diet-induced obesity mice with previously established insulin resistance. In parallel with the amelioration of insulin resistance, circulating LBP concentration was decreased. 25 In a similar way to LBP, the change in LPS concentration ran in parallel with the change in body weight gain and in the area under the 2-h blood glucose response curve (area under the curve) in HFD treatment.
The beneficial effects of metformin in T2DM and obesity are well established. In addition, the data of this study, in which metformin administration decreased LBP (in mice fed normal chow diet) and LPS concentration (in mice fed normal chow and HFD), led to hypothesize that metformin might be useful to prevent HFD-induced metabolic endotoxemia. These findings also led to speculate that metabolic endotoxemia (a circulating LPS-induced proinflammatory state that led to insulin resistance 22 ) could be the linkage between circulating LBP and obesity-related insulin resistance.
Circulating LBP was also associated with inflammatory parameters (leukocyte count, sTNFR1 and sTNFR2), mainly, in subjects with T2DM. Serum concentrations of soluble TNFR2 are believed to reflect the degree of activation of the TNF system. 26 In addition, circulating LBP concentration was in concordance with other possible candidate markers of obesity-related insulin resistance and closely associated with innate immune system response such as C-reactive protein, 27 bactericidal/permeability-increasing 14 and complement factor B. 18 Otherwise, the strong circulating LBP reduction after fat mass loss opens new perspectives. The decrease in LBP concentration after weight loss ran in parallel with the decrease in leptin concentration, a protein produced mainly in adipocytes that circulates in proportion with body fat mass, 28 and with the decrease of complement factor B concentration, which has been reported to be expressed in human adipose tissue and adipocytes. 18 Further studies are necessary to explore these fascinating relationships.
The main limitation of this study is that the findings do not imply causality. Future experiments are necessary to evaluate the possible effects of LBP promoting insulin resistance in adipocytes and hepatocytes and/or the possible role of insulin resistance on LBP production in hepatocytes.
